Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The...
-
Upload
amberly-robbins -
Category
Documents
-
view
218 -
download
0
Transcript of Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The...
![Page 1: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/1.jpg)
Technology and Knowledge: The Two Driving Forces of DM
Innovation and ImpactPresented at
The Disease Management ColloqiumJune, 2004
Harry L. Leider, MD, MBAPresident
IFI Health Solutions
[email protected] (410) 252-7361
![Page 2: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/2.jpg)
2
© Harry L . Leider, MD. MBA
Next Generation Challenges for DM
1. Improve the impact of existing programs
2. Develop new DM programs that can reduce costs and improve quality – for NEW diseases and patient populations
– Beyond CHF, Diabetes, Asthma, COPD, and CAD….
3. Reduce the operational costs of current DM programs
– Leverage valuable and expensive nursing personnel
![Page 3: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/3.jpg)
3
© Harry L . Leider, MD. MBA
In other words, the challenge is to simultaneously improve the efficiency and effectiveness of Quality Improvement programs…..
• Efficiency can be significantly improved by deploying better technologies…
• Effectiveness is improved by deploying better clinical and care management knowledge…
![Page 4: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/4.jpg)
4
© Harry L . Leider, MD. MBA
Types of Care Management Knowledge
• Clinical guidelines (this is the easy one!)
• Methods for identifying appropriate patients
• Risk stratification methodologies
• Interventions to create behavioral change & empower patients
• Interventions to encourage providers to follow evidence-based medicine
• Approaches to managing a complex case
– Assessment, Planning, Coordination, Advocacy
• Tools to assess and monitor patients
• Approaches to defining and measuring outcomes
![Page 5: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/5.jpg)
5
© Harry L . Leider, MD. MBA
Future “Killer Apps”?
• EMR• Remote Patient Monitoring• E-Prescribing• POE/Computerized Reminders• Care Management IT Platforms• Predictive Modeling• Web-based patient education and interactivity
Personal Medical Record and Self Care• Self Monitoring Tools• Secure messaging (physician to patient)• Patient reminder systems
![Page 6: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/6.jpg)
6
© Harry L . Leider, MD. MBA
Electronic Medical Record: Benefits
• Increased accuracy of data
• Sharing of data between providers across geographic sites
• Automatic reminders for preventive interventions or F/U visits
• Tracking and trending of data
• Profiling of outcomes
• Automated guidelines
![Page 7: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/7.jpg)
Logician
• Electronic Medical Record (EMR) System• Ambulatory care
– 500+ installs– 17,000 licenses – Approx. 14 Million patient records nationwide
![Page 8: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/8.jpg)
8
© Harry L . Leider, MD. MBA
Vision – Real Time Web Reports
![Page 9: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/9.jpg)
9
© Harry L . Leider, MD. MBA
Vision - Web Reports
![Page 10: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/10.jpg)
10
© Harry L . Leider, MD. MBA
Inpatient EMR/Computerized Reminders
• RCT of computerized reminders for preventive Rx• 6,372 patients and 10,065 admits over 18 months• Physicians in intervention group viewed reminders when
using POE
Preventive Rx Control Group Intervention Group
Pneumovax 0.8% 35.8%
Flu Vaccine 1.0% 51.4%
Heparin SQ 18.9% 32.2%
CV/ASA 27.6% 36.4%
NEJM,Sept 27, 2001:965-970
![Page 11: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/11.jpg)
11
© Harry L . Leider, MD. MBA
Quality and the EMR
• A POE/EMR system offers user organizations:– Reduced errors– Disease management reporting– Quality of care reporting– Practice profiling– Computerized reminders – The ability to use ambulatory data for clinical research– A potential revenue stream from data
![Page 12: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/12.jpg)
12
© Harry L . Leider, MD. MBA
E-Prescribing
Provides integrated prescribing, drug reference, and charge capture in one wireless handheld device.
• Fully connected, from a Palm to 95% of pharmacies• Accessible anywhere with a wireless handheld device• Secure with an encryption technology• Easy to use
![Page 13: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/13.jpg)
13
© Harry L . Leider, MD. MBA
In 1996, a Texas jury decided that due to illegibility, this prescription caused the patient to die.
The patient received not only the wrong medication, but at 8x the drug's usually recommended strength
Experts believe that 25% of medication errors might be related to illegible handwriting.
--CNN Health
![Page 14: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/14.jpg)
14
© Harry L . Leider, MD. MBA
E-Prescription Capture: Allscripts EP module
1. Select Patient
2. Select Diagnosis
3. View Formulary & Select Drug
4. Confirm Dosing & Print/Fax Rx
EPrescribing through a formulary list strongly encourages compliance
1. Physician clearly sees preferred v. non-preferred drugs
Physician risks callbacks from pharmacists, plans and patients by prescribing off formulary
2. It takes longer to prescribe off formulary
![Page 15: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/15.jpg)
15
© Harry L . Leider, MD. MBA
EMRs contain Electronic Prescribing modules within comprehensive patient information systems
Full prescribing capability including search & selection from formulary lists
![Page 16: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/16.jpg)
16
© Harry L . Leider, MD. MBA
Projected Adoption Rates: Various accelerators and
inhibitors could cause rapid or slowed adoption
5%
2003
2004
2005
25%
15%
35%
2006
2008
2010
2012
20% Penetration
Rapid Adoption2005*
Slow Adoption2011
Moderate Adoption2007-2008
40% express future interest in EP, given the right system**
(short term limit unless significant mandates are introduced – no major
ones proposed yet)
** CyberDialogue / Manhattan Research, Physician Surveys* Manhattan Research expects EP usage to reach 13% & 17% in 2003 & 2004, respectively
Confidence Intervals
___ Rapid Adoption
___ Moderate Adoption
___ Slow Adoption
![Page 17: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/17.jpg)
17
© Harry L . Leider, MD. MBA
EP Could Provide a Powerful Tool to Engage Providers in DM
• 5-10% of prescribing physicians in the US currently use EP tools actively
• Short term limit on EP of ~40% To get beyond there within 10 years would require either:– usage mandates (Feds, MCOs, employers)
• EP can provide a powerful DM tool to:
– disseminate guidelines
– provide care management “prompts”
– share confidential provider profiles and outcomes
* US Department of Justice
![Page 18: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/18.jpg)
18
© Harry L . Leider, MD. MBA
Remote Patient Monitoring
• Monitor chronically ill patients
• Prevent hospital admissions
• Tracking/trend clinical data
• Data transmitted via phone
• Cost plummeting ($30/month)
• Center of Excellence Tool
• Already used by many DM vendors and some MCOs
![Page 19: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/19.jpg)
![Page 20: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/20.jpg)
20
© Harry L . Leider, MD. MBA
Problems With Web Content
![Page 21: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/21.jpg)
21
© Harry L . Leider, MD. MBA
![Page 22: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/22.jpg)
22
© Harry L . Leider, MD. MBA
![Page 23: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/23.jpg)
23
© Harry L . Leider, MD. MBA
![Page 24: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/24.jpg)
Care Management Platform
Technology
CaseAlert, DxCG
Predictive Modeling
M&R, Optimed, Interqual
Utilization Management
Protocols
Clinical algorithmsCM knowledge
Disease and Case Management Content
Knowledge
Knowledge Embedded in Care Management Technology
Increased Efficiency and Effectiveness
Data Exchange
![Page 25: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/25.jpg)
25
© Harry L . Leider, MD. MBA
What is DM “Clinical Content”?
The 5 Components1. Care Manager workflow tools
2. Clinical best practices• Evidence-based medicine
• Expert opinion
3. Care management processes (for providers and patients)
4. Reporting tools• To patients• To providers
5. Recommended outcomes metrics
![Page 26: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/26.jpg)
26
© Harry L . Leider, MD. MBA
Patient Identification and Primary Risk Stratification
Clinical Rules:
Diabetes and MI within 91 days
CVD plus multiple risk factors: no admissions
Diabetes, CVD, high lipids: no lipid
lowering medications
![Page 27: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/27.jpg)
27
© Harry L . Leider, MD. MBA
![Page 28: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/28.jpg)
28
© Harry L . Leider, MD. MBA
Clinical “Branching Logic”
Business Objects Designer
H a v e y o uh a d a n M I ?
M I w ith in th ela s t 1 2
m o n th s?
I n st r uc t p a t ie n t s o nsign s a n d Sx .
o f a M I
H isto r y o fc a r d ia cr e h a b ?
Ed u c a te p a t ie n to n c a rd ia c re h a b
P at ien t o n aB eta-b lo ck er?
E duc a t e o n be n e f ito f a be t a - blo c k e r
P at ien t o na A C E ?
Ed u c a te o nb e n e fit o f A CE
C o n t ra. toB -b lo ck er?
C o n t ra toA C E ?
W o u ld y o u d or e h a b n o w ?
P atien t L e tte r s & R ep o r ts
Y
N
N
Y
N N
N
N
N
Y
P h y s ic ian Aler ts & L ette r s
![Page 29: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/29.jpg)
29
© Harry L . Leider, MD. MBA
![Page 30: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/30.jpg)
30
© Harry L . Leider, MD. MBA
![Page 31: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/31.jpg)
31
© Harry L . Leider, MD. MBA
![Page 32: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/32.jpg)
32
© Harry L . Leider, MD. MBA
![Page 33: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/33.jpg)
33
© Harry L . Leider, MD. MBA
![Page 34: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/34.jpg)
34
© Harry L . Leider, MD. MBA
The “Help” Function
“The main treatment goal for survivors of an MI is to prevent a recurrent MI. Patients who recently had an MI should be strongly encouraged to enroll in cardiac rehabilitation. In all patients, the first step to preventing another MI is to develop a plan to modify lifestyle-related risk factors. Patients should quit smoking, lose weight if necessary, exercise regularly, follow a diet that is high in fiber and low in fat, and manage stress.”
“All patients who have suffered a heart attack should be started on daily aspirin therapy unless contraindicated or intolerable. In addition, the American Heart Association (AHA) guidelines recommend that all post-MI patients receive beta blockers and ACE inhibitors to help reduce the workload of the heart following the myocardial injury unless contraindicated. ACE inhibitors are particularly important in decreased myocardial function following an MI to reduce the risk for developing heart failure. Both ACE-inhibitors and beta blockers should be continued indefinitely.
“Finally, because of documented efficacy in preventing a recurrent heart attack, the AHA recommends all patients with elevated LDL-cholesterol levels (>100mg/dl) should be given lipid-lowering therapy with an HMG CoA- reductase inhibitor, also known as a statin.”
![Page 35: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/35.jpg)
35
© Harry L . Leider, MD. MBA
Letters, Action Plans, and Reports
• Targeted at patients– Health risk assessments– Educational materials– Ask-your-doctor guides
• Targeted at providers– Program participation notices– Alerts and prompts
• Program level outcomes reports
![Page 36: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/36.jpg)
36
© Harry L . Leider, MD. MBA
The Best Care Management Programs
• Have talented, well-trained care managers
• Have state-of-the art care management knowledge and processes
• Imbed their knowledge in technology to:– Increase program efficiency– Provide easy access to care management knowledge– Increase ROI of DM programs– Enhance the ability to analyze data and improve
program intervention– More effectively communicate with patients and
providers
![Page 37: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/37.jpg)
37
© Harry L . Leider, MD. MBA
What Will be a Killer App?
• We don’t really know yet?• Technology market is very fragmented• Cost and capital is still a major issues• Remember Betamax!
Nonetheless, we believe that EMRs, E-prescribing, web-based tools, RPM, and care management platforms are the most likely “winners”
![Page 38: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/38.jpg)
38
© Harry L . Leider, MD. MBA
Forces Driving Technology Adoption
• The need to improve patient safety• Aging of the population: need to managed
multiple co-morbidities• Spiraling healthcare costs• Consumer adoption of Internet
tools/technologies• Employer-driven consumer models• Increased physician acceptance of technology• Growth of Disease Management programs
![Page 39: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/39.jpg)
39
© Harry L . Leider, MD. MBA
Interventions across the population
-to-face
,
IntelligentRPM with Web Interaction
Web Only
TeleWeb(Telecare Linked
with Web)
Net PotentialSavings
Net Savings
Wellness At Risk Critical Episode High AcuityChronically ill
Population – Breakdown by Presence of Chronic Disease
Seamless integration ofTelecare, Internet, smart
Devices, person to person
-deployed according toseverity
TargetedDevices(RPM)
Baseline Medical Costs
Recurrence
Technology and Disease Management
![Page 40: Technology and Knowledge: The Two Driving Forces of DM Innovation and Impact Presented at The Disease Management Colloqium June, 2004 Harry L. Leider,](https://reader035.fdocuments.in/reader035/viewer/2022062421/56649dc75503460f94abbbb5/html5/thumbnails/40.jpg)
40
© Harry L . Leider, MD. MBA
Discussion